Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 2Phase 1 1

Status

Active not recruiting 6Recruiting 4Completed 2Approved for marketing 1

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

Thoracic 5NET 1Endocrine 1

Conditions

Small Cell Lung Carcinoma 4Neuroendocrine Tumors 1Neoplasms 1Lung Neoplasms 1Bites and Stings 1

Interventions

pembrolizumab 437Carboplatin 322Nivolumab 292Cyclophosphamide 281Specimen Handling 271Magnetic Resonance Spectroscopy 257Cisplatin 253Paclitaxel 248Radiotherapy 229Gemcitabine 183Biopsy 182Dexamethasone 181durvalumab 168atezolizumab 151Rituximab 138Doxorubicin 135Lenalidomide 134Bevacizumab 133Docetaxel 131Ipilimumab 129Capecitabine 120Radiation 118Oxaliplatin 114Radiosurgery 113Pemetrexed 112Etoposide 111Fluorouracil 110venetoclax 106fludarabine 106Prednisone 97

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Active not recruiting × AMG 757 × Clear all
NCT06117774 2026-04-29

DeLLphi-306

Amgen

Phase 3 Active not recruiting
404 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT06502977 2026-04-15

DeLLphi-307

Amgen

Phase 2 Active not recruiting
32 enrolled 9 charts
EndocrineNET

Neoplasms, Neuroendocrine Tumors

NCT05361395 2026-03-03

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Amgen

Phase 1 Active not recruiting
184 enrolled
Thoracic

Bites and Stings, Lung Neoplasms

NCT06745323 2026-03-03

DeLLphi-309

Amgen

Phase 2 Active not recruiting
252 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT05740566 2026-01-05

DeLLphi-304

Amgen

Phase 3 Active not recruiting
509 enrolled 11 charts 1 FDA
Thoracic

Small Cell Lung Carcinoma

NCT06211036 2025-12-17

DeLLphi-305

Amgen

Phase 3 Active not recruiting
563 enrolled
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡